Quantcast

Latest Glioma Stories

2014-06-10 12:31:14

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Recurrent Malignant Glioma - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/diseases/recurrent_malignant_glioma_pipeline_review_h1_2013.html Recurrent Malignant Glioma - Pipeline Review, H1 2014SummaryGlobal Markets Direct's, 'Recurrent Malignant Glioma - Pipeline Review, H1 2014', provides an overview of the Recurrent Malignant Glioma's therapeutic pipeline.This report...

2014-06-09 14:11:57

University of California - San Francisco A double-edged sword, gene variants may promote overall health while increasing risk of gliomas New genomic research led by UC San Francisco (UCSF) scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas. The genetic...

2014-06-03 13:06:47

Duke University Medical Center A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma. The researchers identified a genetic mutation in the tumor cells that plays a role in both the growth and the death of a cell. Additionally, the mutation to the newly identified gene may also contribute to the tumor's resistance to...

2014-05-31 16:20:13

Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response SAN FRANCISCO, May 31, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of...

2014-05-31 08:20:41

VANCOUVER, British Columbia and MENLO PARK, Calif., May 31, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago. In...

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-22 08:29:48

In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ -- Tocagen Inc. today announced multiple scientific contributions at the American Society of Gene and Cell Therapy (ASGCT) 17(th) Annual Meeting, held May 21 to 24, 2014 at the Marriott Wardman Park in Washington, DC. At the ASGCT Annual Meeting, data from clinical and preclinical studies of Toca 511 will be presented in two podium presentations:...

2014-05-20 08:31:42

CALGARY, May 20, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN(®) to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website at http://abstracts.asco.org. The conference is being held from May 30(th) to June 3(rd), 2014 in Chicago, Illinois. "Treatment...

2014-05-16 08:26:16

30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to provide an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma multiforme (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 6 and advanced to Cohort 7. DelMar most recently presented...

2014-05-06 23:03:44

Wildlife Correspondent to Help Raise Awareness of 700,000 Living with a Brain Tumor Chicago, IL (PRWEB) May 06, 2014 Inspired by his daughter’s courageous battle against brain tumors, Wildlife Correspondent Jack Hanna has teamed up with the American Brain Tumor Association to raise awareness and promote greater understanding of the disease in observation of Brain Tumor Awareness Month this May. At the age of 2, Hanna’s youngest daughter, Julie, was diagnosed with leukemia and went...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related